经皮免疫亲水重组 gp100 蛋白诱导抗原特异性细胞免疫应答。
Transcutaneous immunization with hydrophilic recombinant gp100 protein induces antigen-specific cellular immune response.
机构信息
Sharett Institute of Oncology, Hadassah Medical Organization, Jerusalem, Israel.
出版信息
Cell Immunol. 2010;266(1):98-103. doi: 10.1016/j.cellimm.2010.09.003. Epub 2010 Sep 18.
Abstract
The objective of this study was to evaluate the potential of transcutaneous immunization with tumor antigen to induce cell-mediated immunity. For this purpose, hydrophilic recombinant gp100 protein (HR-gp100) was topically applied on human intact skin in vitro, and used as a vaccine in a mouse model. We demonstrate that HR-gp100 permeates into human skin, and is processed and presented by human dendritic cells. In a mouse model, an HR-gp100-based vaccine triggered antigen-specific T cell responses, as shown by proliferation assays, ELISA and intracellular staining for IFN-γ. Transcutaneous antigen delivery may provide a safe, simple and effective method to elicit cell-mediated immunity.
摘要
本研究旨在评估经皮免疫肿瘤抗原诱导细胞免疫的潜力。为此，我们在体外将亲水性重组 gp100 蛋白（HR-gp100）经皮应用于人体完整皮肤，并将其作为疫苗用于小鼠模型。我们证明 HR-gp100 能够渗透进入人体皮肤，并由人树突状细胞进行加工和呈递。在小鼠模型中，基于 HR-gp100 的疫苗引发了抗原特异性 T 细胞反应，这可通过增殖试验、ELISA 和 IFN-γ的细胞内染色来证明。经皮抗原传递可能为诱导细胞免疫提供一种安全、简单和有效的方法。
相似文献
1
Transcutaneous immunization with hydrophilic recombinant gp100 protein induces antigen-specific cellular immune response.
Cell Immunol. 2010;266(1):98-103. doi: 10.1016/j.cellimm.2010.09.003. Epub 2010 Sep 18.
2
gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
Clin Cancer Res. 2004 Jan 15;10(2):668-80. doi: 10.1158/1078-0432.ccr-0095-03.
3
Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Cancer J Sci Am. 1998 Sep-Oct;4(5):316-23.
4
CD204 suppresses large heat shock protein-facilitated priming of tumor antigen gp100-specific T cells and chaperone vaccine activity against mouse melanoma.
J Immunol. 2011 Sep 15;187(6):2905-14. doi: 10.4049/jimmunol.1100703. Epub 2011 Aug 10.
5
Covalent crosslinking of tumor antigens stimulates an antitumor immune response.
Vaccine. 2010 Sep 14;28(40):6613-20. doi: 10.1016/j.vaccine.2010.07.060. Epub 2010 Aug 2.
6
A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model.
Vaccine. 2015 Sep 11;33(38):4798-806. doi: 10.1016/j.vaccine.2015.07.081. Epub 2015 Aug 1.
7
Syngeneic murine model for prostate cancer using RM1 cells transfected with gp100.
Prostate. 2020 Apr;80(5):424-431. doi: 10.1002/pros.23957. Epub 2020 Feb 3.
8
Recombinant gp100 protein presented by dendritic cells elicits a T-helper-cell response in vitro and in vivo.
Int J Cancer. 1999 Nov 12;83(4):547-54. doi: 10.1002/(sici)1097-0215(19991112)83:4<547::aid-ijc18>3.0.co;2-6.
9
Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
J Mol Med (Berl). 2003 Sep;81(9):585-96. doi: 10.1007/s00109-003-0472-5. Epub 2003 Aug 21.
10
Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
Cancer Res. 2006 May 1;66(9):4943-51. doi: 10.1158/0008-5472.CAN-05-3396.
引用本文的文献
1
Gene network-based and ensemble modeling-based selection of tumor-associated antigens with a predicted low risk of tissue damage for targeted immunotherapy.
J Immunother Cancer. 2024 May 9;12(5):e008104. doi: 10.1136/jitc-2023-008104.
2
modulation of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes.
Front Immunol. 2023 Jun 8;14:1180997. doi: 10.3389/fimmu.2023.1180997. eCollection 2023.
3
Prognostic value of B cells in cutaneous melanoma.
Genome Med. 2019 May 28;11(1):36. doi: 10.1186/s13073-019-0647-5.
4
Cancer immunotherapy: broadening the scope of targetable tumours.
Open Biol. 2018 Jun;8(6). doi: 10.1098/rsob.180037.
5
The effect of haptens on protein-carrier immunogenicity.
Immunology. 2015 Jan;144(1):116-26. doi: 10.1111/imm.12356.
6
Multi-compartmental vaccine delivery system for enhanced immune response to gp100 peptide antigen in melanoma immunotherapy.
Pharm Res. 2012 Dec;29(12):3393-403. doi: 10.1007/s11095-012-0834-1. Epub 2012 Jul 18.
本文引用的文献
1
Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response.
J Exp Med. 2009 Apr 13;206(4):849-66. doi: 10.1084/jem.20081382. Epub 2009 Mar 30.
2
Characterization of the class I-restricted gp100 melanoma peptide-stimulated primary immune response in tumor-free vaccine-draining lymph nodes and peripheral blood.
Clin Cancer Res. 2009 Apr 1;15(7):2541-51. doi: 10.1158/1078-0432.CCR-08-2806. Epub 2009 Mar 24.
3
Capture of tumor cell membranes by trogocytosis facilitates detection and isolation of tumor-specific functional CTLs.
Cancer Res. 2008 Mar 15;68(6):2006-13. doi: 10.1158/0008-5472.CAN-07-3119.
4
A melanoma multiepitope polypeptide induces specific CD8+ T-cell response.
Cell Immunol. 2007 Nov-Dec;250(1-2):24-30. doi: 10.1016/j.cellimm.2008.01.001. Epub 2008 Feb 13.
5
Transcutaneous anti-influenza vaccination promotes both CD4 and CD8 T cell immune responses in humans.
J Immunol. 2008 Feb 1;180(3):1482-9. doi: 10.4049/jimmunol.180.3.1482.
6
Melanoma vaccines.
Semin Oncol. 2007 Dec;34(6):516-23. doi: 10.1053/j.seminoncol.2007.09.013.
7
Taming cancer by inducing immunity via dendritic cells.
Immunol Rev. 2007 Dec;220:129-50. doi: 10.1111/j.1600-065X.2007.00575.x.
8
Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptide.
J Immunother. 2007 Jul-Aug;30(5):533-43. doi: 10.1097/CJI.0b013e3180335b5e.
9
Immunological activation following transcutaneous delivery of HR-gp100 protein.
Vaccine. 2007 Jun 6;25(23):4564-70. doi: 10.1016/j.vaccine.2007.04.025. Epub 2007 Apr 25.
10
Initiation of adaptive immune responses by transcutaneous immunization.
Immunol Lett. 2007 Mar 15;109(1):13-20. doi: 10.1016/j.imlet.2007.01.007. Epub 2007 Feb 12.
Zotero 插件